ArticleLeukemia2024

Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.

Marie Sébert et al.PubMed ↗Publisher ↗

No numbers read from the abstract.